Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

275% rise in dementia cases for Australia over next 40 years: Study

According to an Access Economics study commissioned by the Alzheimer’s Australia the number of Victorian dementia patients will quadruple in the next 40 years. At present the figures stand at 66,000 and are expected to touch 246,000 in 2050. The rise is an alarming 275% and is fueled by population growth, reduced physical activity, and an increasingly ageing population. Alzheimer’s Australia warns Victorian Health authorities to start planning for measures to curb the epidemic.

19 May 2010

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).

19 May 2010

Research team converts astroglia into two main classes of cortical neurons

The research team led by Professor Magdalena Götz of Helmholtz Zentrum München and Ludwig-Maximilians-Universität (LMU) Munich reports a major step forward in discovering a therapy for neurodegenerative diseases such as Alzheimer's or stroke. The researchers were able to convert glial cells of the brain into two different functional classes of neurons. The findings are published on May 18th in the renowned journal PLoS Biology.

19 May 2010

Study examines impact of APOE ε4 on cognitive function, brain anatomy in AD patients

In the most comprehensive study to date, neurologists have clearly identified significant differences in the ways that Alzheimer's disease affects patients with and without the apolipoprotein E ε4 gene, a known genetic risk factor for the neurodegenerative disease, using a combination of cognitive and neuroanatomic measures. The study found that this gene influences the way the disease manifests, even at its mildest clinical stages.

19 May 2010

TPP raises £9.6M to develop early-stage pre-clinical drug candidates

TPP Global Development, an innovative drug development company, announced today it has raised £9.6m which will be used to execute the Company's strategy to develop early-stage pre-clinical drug candidates.

19 May 2010

Diabetic patients with limited health literacy are at higher risk for hypoglycemia: Study

People with diabetes who have limited health literacy are at higher risk for hypoglycemia or low blood sugar, according to a new study from researchers at the University of California, San Francisco and the Kaiser Permanente Division of Research in Oakland, CA.

19 May 2010

Taking the final step from the bench to the hospital or clinic bedside

A new Regenstrief Institute and Indiana University Center for Aging Research (IUCAR) study provides effective strategies to help hospital systems, physicians and other care providers to overcome end zone hurdles and actually take evidence-based research to the patient’s hospital or clinic bedside.

18 May 2010

Taking the final step from the bench to the hospital or clinic bedside

18 May 2010

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

Vect-Horus is a biotechnology company based on the scientific work of Dr. Michel Khrestchatisky and specializes in the development of peptide and pseudo-peptide-based vector molecules for drug targeting and delivery to the central nervous system (CNS).

18 May 2010

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

ImmunoCellular Therapeutics, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells ("CSCs") which makes it promising for immunological targeting.

18 May 2010

Pfizer, Washington University announce indications discovery collaboration

In a first-of-a-kind collaboration between academia and industry, Pfizer Inc. will give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds.

18 May 2010

Eisai calls on Alzheimer's patients and caregivers to nominate pharmacists for 2010 C.A.R.E. Pharmacy Award

Eisai Inc., in coordination with the Alzheimer's Association, calls on individuals with Alzheimer's disease and their caregivers across America to nominate local pharmacists for the 2010 C.A.R.E. Pharmacy Award. This award recognizes the vital role that pharmacists play in helping the estimated 5.3 million Americans living with Alzheimer's disease and their almost 11 million caregivers.

18 May 2010

Caffeine normalizes brain function and prevents cognitive decline

Although caffeine is the most widely consumed psychoactive drug worldwide, its potential beneficial effect for maintenance of proper brain functioning has only recently begun to be adequately appreciated. Substantial evidence from epidemiological studies and fundamental research in animal models suggests that caffeine may be protective against the cognitive decline seen in dementia and Alzheimer's disease (AD).

18 May 2010

Altered blood flow leads to falls in elderly people: Research

A new study shows that altered blood flow in the brain due to high blood pressure and other conditions may lead to falls in elderly people. The research will be published in the May 18, 2010, issue of Neurology, the medical journal of the American Academy of Neurology. Each year, unintentional falls in the United States account for more than 16,000 deaths and 1.8 million emergency room visits.

18 May 2010

Cortex first-quarter net income increases to $0.08 per share

Cortex Pharmaceuticals, Inc. reported net income of approximately $5,596,000, or $0.08 per share for the quarter ended March 31, 2010 compared with a net loss of $3,168,000, or $0.07 per share for the corresponding prior year period, with the difference reflecting revenues from the Company's March 2010 transaction with Biovail Laboratories International SRL (Biovail).

17 May 2010

Soliant Health opens up voting for 20 Most Beautiful Hospitals contest

Soliant Health, a leading specialty healthcare staffing provider and part of Adecco Group, has opened up voting for its second annual 20 Most Beautiful Hospitals contest.

15 May 2010

United Spinal Association and ICS co-sponsor first annual conference to empower women with disabilities

United Spinal Association and Independence Care System (ICS), are co-sponsoring the first annual conference to improve the lives, health, and well-being of women with disabilities.

15 May 2010

Power3 Medical Products files provisional patent applications with USPTO

Power3 Medical Products, Inc. announced today that it has filed two provisional patent applications with the United States Patent and Trademark Office (USPTO) - one on Alzheimer's disease specific differential diagnosis in the clinical setting and the other on important differences in pathophysiology and therapeutic options for the genetically distinct groups of Alzheimer's disease patients.

15 May 2010

Robertson Foundation gifts NYSCF $27 million

The New York Stem Cell Foundation (NYSCF) has received a grant of $27 million from the Robertson Foundation, established by Julian and Josie Robertson.

15 May 2010

Foundation Venture Capital Group makes initial investment of $175,000 to develop test to diagnose AD

As many as 5.3 million Americans, and 35 million people worldwide, are living with Alzheimer's disease, a devastating neurodegenerative illness characterized by memory loss, cognitive decline and widespread destruction of neurons in the brain. Today, there is no definitive diagnosis for the disease, and no treatment to cure it.

15 May 2010

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

275% rise in dementia cases for Australia over next 40 years: Study

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Research team converts astroglia into two main classes of cortical neurons

Study examines impact of APOE ε4 on cognitive function, brain anatomy in AD patients

TPP raises £9.6M to develop early-stage pre-clinical drug candidates

Diabetic patients with limited health literacy are at higher risk for hypoglycemia: Study

Taking the final step from the bench to the hospital or clinic bedside

Taking the final step from the bench to the hospital or clinic bedside

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

Pfizer, Washington University announce indications discovery collaboration

Eisai calls on Alzheimer's patients and caregivers to nominate pharmacists for 2010 C.A.R.E. Pharmacy Award

Caffeine normalizes brain function and prevents cognitive decline

Altered blood flow leads to falls in elderly people: Research

Cortex first-quarter net income increases to $0.08 per share

Soliant Health opens up voting for 20 Most Beautiful Hospitals contest

United Spinal Association and ICS co-sponsor first annual conference to empower women with disabilities

Power3 Medical Products files provisional patent applications with USPTO

Robertson Foundation gifts NYSCF $27 million

Foundation Venture Capital Group makes initial investment of $175,000 to develop test to diagnose AD

Innovation in neuroscience drug discovery - eBook eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Innovation in neuroscience drug discovery - eBook eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in